Recent Performance of Invion Ltd. (IVX.AX)
In the most recent trading session, Invion Ltd. experienced a decline of 5.26 % over a 24‑hour period concluding at 12:06 AM Central Europe on Thursday, 22 October 2026. The share price currently trades at approximately AUD 0.03 on major exchanges. With a total outstanding supply of 115.3 million shares, the company’s market capitalisation stands at AUD 4.2 million. Only about AUD 11 000 worth of shares were exchanged over the last 24 hours, reflecting a modest trading volume.
Since the end of the previous month, Invion’s shares have fallen by 7.69 %. The 200‑day simple moving average sits at AUD 0.06, providing a short‑term reference point for price movements. The highest valuation recorded in the past year was AUD 0.11 on 23 December 2025, while the 52‑week low was AUD 0.03 on 6 July 2026, underscoring the stock’s recent volatility.
Context from Peer Performance
To situate Invion’s performance within its sector, the following snapshot of peer activity over the preceding 24 hours is provided:
| Company | 24‑Hour Move | Current Price | Market Capitalisation | P/E Ratio |
|---|---|---|---|---|
| Newpeak Metals (NPM.AX) | 0 % | AUD 0.01 | AUD 4.9 million | 0.6 |
| Datadot (DDT.AX) | 0 % | AUD 0.00 | AUD 4.9 million | 0.2 |
| Eve Health (EVE.AX) | 0 % | AUD 0.02 | AUD 4.9 million | — |
| Infocus (IFG.AX) | –11.11 % | AUD 0.01 | AUD 4.9 million | — |
| Anagenics (AN1.AX) | 0 % | AUD 0.00 | AUD 4.9 million | 12.5 |
The data illustrate a broader trend of modest to negative price movement across comparable companies, with Infocus experiencing the most pronounced decline within the cohort.
Company Overview
Invion Ltd. is headquartered in South Melbourne, Australia, and operates within the health‑care sector. The firm specializes in transforming photodynamic therapy (PDT) into novel and effective cancer treatments. Its primary markets are Australia and New Zealand, and further information can be found on its website at www.inviongroup.com . Invion is listed on the ASX All Markets stock exchange, providing investors with regulated access to its equity.
This article presents factual market data and contextual peer analysis to aid stakeholders in understanding Invion Ltd.’s recent performance and positioning within the broader health‑science sector.
